Terms: = Leukemia AND FOXP1, MGC12942, 27086, ENSG00000114861, hFKH1B, MGC99551, FLJ23741, QRF1, 12CC4, HSPC215, MGC88572 AND Prognosis
11 results:
1. Rapid molecular response to dasatinib in Ph-like acute lymphoblastic leukemia patients with ABL1 rearrangements: case series and literature review.
Tan KW; Zhu YY; Qiu QC; Wang M; Shen HJ; Huang SM; Cao HY; Wan CL; Li YY; Dai HP; Xue SL
Ann Hematol; 2023 Sep; 102(9):2397-2402. PubMed ID: 37103615
[TBL] [Abstract] [Full Text] [Related]
2. BCR-ABL1-like B-Lymphoblastic leukemia/Lymphoma with foxp1-ABL1 Rearrangement: Comprehensive Laboratory Identification Allowing Tyrosine Kinase Inhibitor Use.
Yenamandra AK; Kaviany S; Borinstein SC; Friedman DL; Kovach AE
Lab Med; 2019 Oct; 50(4):401-405. PubMed ID: 30938769
[TBL] [Abstract] [Full Text] [Related]
3. MicroRNA miR-34a downregulates foxp1 during DNA damage response to limit BCR signalling in chronic lymphocytic leukaemia B cells.
Cerna K; Oppelt J; Chochola V; Musilova K; Seda V; Pavlasova G; Radova L; Arigoni M; Calogero RA; Benes V; Trbusek M; Brychtova Y; Doubek M; Mayer J; Pospisilova S; Mraz M
Leukemia; 2019 Feb; 33(2):403-414. PubMed ID: 30111844
[TBL] [Abstract] [Full Text] [Related]
4. Prognostic impact of kinase-activating fusions and IKZF1 deletions in pediatric high-risk B-lineage acute lymphoblastic leukemia.
Tran TH; Harris MH; Nguyen JV; Blonquist TM; Stevenson KE; Stonerock E; Asselin BL; Athale UH; Clavell LA; Cole PD; Kelly KM; Laverdiere C; Leclerc JM; Michon B; Schorin MA; Welch JJG; Reshmi SC; Neuberg DS; Sallan SE; Loh ML; Silverman LB
Blood Adv; 2018 Mar; 2(5):529-533. PubMed ID: 29507076
[TBL] [Abstract] [Full Text] [Related]
5. foxp1 Expression in Normal and Neoplastic Erythroid and Myeloid Cells.
Lovrić E; Pavlov KH; Korać P; Dominis M
Coll Antropol; 2015 Sep; 39(3):755-9. PubMed ID: 26898077
[TBL] [Abstract] [Full Text] [Related]
6. foxp1 suppresses immune response signatures and MHC class II expression in activated B-cell-like diffuse large B-cell lymphomas.
Brown PJ; Wong KK; Felce SL; Lyne L; Spearman H; Soilleux EJ; Pedersen LM; Møller MB; Green TM; Gascoyne DM; Banham AH
Leukemia; 2016 Mar; 30(3):605-16. PubMed ID: 26500140
[TBL] [Abstract] [Full Text] [Related]
7. Different biological risk factors in young poor-prognosis and elderly patients with diffuse large B-cell lymphoma.
Horn H; Ziepert M; Wartenberg M; Staiger AM; Barth TF; Bernd HW; Feller AC; Klapper W; Stuhlmann-Laeisz C; Hummel M; Stein H; Lenze D; Hartmann S; Hansmann ML; Möller P; Cogliatti S; Pfreundschuh M; Trümper L; Loeffler M; Glass B; Schmitz N; Ott G; Rosenwald A;
Leukemia; 2015 Jul; 29(7):1564-70. PubMed ID: 25687653
[TBL] [Abstract] [Full Text] [Related]
8. miR in CLL: more than mere markers of prognosis?
Kater AP; Eldering E
Blood; 2014 Jul; 124(1):2-4. PubMed ID: 24993874
[TBL] [Abstract] [Full Text] [Related]
9. Non-IG aberrations of foxp1 in B-cell malignancies lead to an aberrant expression of N-truncated isoforms of foxp1.
Rouhigharabaei L; Finalet Ferreiro J; Tousseyn T; van der Krogt JA; Put N; Haralambieva E; Graux C; Maes B; Vicente C; Vandenberghe P; Cools J; Wlodarska I
PLoS One; 2014; 9(1):e85851. PubMed ID: 24416450
[TBL] [Abstract] [Full Text] [Related]
10. Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study.
Visco C; Li Y; Xu-Monette ZY; Miranda RN; Green TM; Li Y; Tzankov A; Wen W; Liu WM; Kahl BS; d'Amore ES; Montes-Moreno S; Dybkær K; Chiu A; Tam W; Orazi A; Zu Y; Bhagat G; Winter JN; Wang HY; O'Neill S; Dunphy CH; Hsi ED; Zhao XF; Go RS; Choi WW; Zhou F; Czader M; Tong J; Zhao X; van Krieken JH; Huang Q; Ai W; Etzell J; Ponzoni M; Ferreri AJ; Piris MA; Møller MB; Bueso-Ramos CE; Medeiros LJ; Wu L; Young KH
Leukemia; 2012 Sep; 26(9):2103-13. PubMed ID: 22437443
[TBL] [Abstract] [Full Text] [Related]
11. Expression of the foxp1 transcription factor is strongly associated with inferior survival in patients with diffuse large B-cell lymphoma.
Banham AH; Connors JM; Brown PJ; Cordell JL; Ott G; Sreenivasan G; Farinha P; Horsman DE; Gascoyne RD
Clin Cancer Res; 2005 Feb; 11(3):1065-72. PubMed ID: 15709173
[TBL] [Abstract] [Full Text] [Related]
